[{"id":"903c1d70-87fc-40b3-9588-5dfb706e286c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05005845","created_at":"2021-08-16T17:54:40.018Z","updated_at":"2024-07-02T16:35:29.020Z","phase":"Phase 2","brief_title":"NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)","source_id_and_acronym":"NCT05005845","lead_sponsor":"NFlection Therapeutics, Inc.","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NFX-179"],"overall_status":"Completed","enrollment":" Enrollment 199","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 10/04/2023","primary_completion_date":" 10/04/2023","study_txt":" Completion: 10/04/2023","study_completion_date":" 10/04/2023","last_update_posted":"2023-11-16"},{"id":"b6e6d6aa-1f12-4033-97bf-25408388ba21","acronym":"","url":"https://clinicaltrials.gov/study/NCT04435665","created_at":"2021-01-18T21:21:22.579Z","updated_at":"2024-07-02T16:36:05.848Z","phase":"Phase 2a","brief_title":"NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)","source_id_and_acronym":"NCT04435665","lead_sponsor":"NFlection Therapeutics, Inc.","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NFX-179"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 08/21/2020","start_date":" 08/21/2020","primary_txt":" Primary completion: 04/08/2021","primary_completion_date":" 04/08/2021","study_txt":" Completion: 04/14/2021","study_completion_date":" 04/14/2021","last_update_posted":"2022-08-09"}]